Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020069402 - CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER

Publication Number WO/2020/069402
Publication Date 02.04.2020
International Application No. PCT/US2019/053596
International Filing Date 27.09.2019
IPC
C07D 237/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
237Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
26condensed with carbocyclic rings or ring systems
28Cinnolines
C07D 403/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 405/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
C07D 417/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 487/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/502 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
502ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 237/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
237Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
26condensed with carbocyclic rings or ring systems
28Cinnolines
C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
C07D 405/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
Applicants
  • GENENTECH, INC. [US]/[US] (US)
  • F. HOFFMANN-LA ROCHE AG [CH]/[CH] (AllExceptUS)
Inventors
  • MALHOTRA, Sushant
  • SIU, Michael
  • WANG, Weiru
  • WEI, BinQing
  • ZHOU, Aihe
  • CHAN, Bryan K.
  • GAZZARD, Lewis J.
  • HEFFRON, Timothy
  • LAINCHBURY, Michael
  • MADIN, Andrew
  • SEWARD, Eileen Mary
  • CARTWRIGHT, Matthew W.
  • GANCIA, Emanuela
  • FAVOR, David
  • FONG, Kin Chiu
  • GOOD, Andrew
  • HU, Yonghan
Agents
  • TIAN, Zong-Qiang Bill
  • AUMAIS, Jonathan
  • BONE, Richard G.A.
  • BUCKWALTER, Brian L.
  • CHANG, Y. Elaine
  • CHI, I. Shannon
  • CLARK, Kevin M.
  • COBURN, Cara M.
  • COLANTONIO, Jessica R.
  • CRISSEY, Todd M.
  • CUI, Steven
  • DAVIS, Bradley E.
  • DAVIS, Jennifer L.
  • DREGER, Ginger
  • FANG, Carol A.
  • GHOSE, Shameek
  • HALL, Robert C.
  • HARLOCKER, Susan
  • HEIDER, Julie A.
  • HESSLER, Amy
  • HILL, Laurie L.
  • JOHNSTON, Sean A.
  • KAFKA, Mark D.
  • KAIS, Samuel
  • KALINOWSKI, Grant E.
  • KRAMMER, Andre
  • LEE, Michelle
  • LEE, Wendy M.
  • LI, Qianru
  • MACKENZIE, Katherine J.
  • MCCLELLAN, Kelly B.
  • REDDY, Daphne
  • ROPP, Traci H.
  • SCHWARTZ, Timothy R.
  • SCOTT, Derek B.
  • SHERMAN, Daniel E.
  • SCHOLZ, Charles K.
  • SHU, Cindy
  • TAN, Anna M.
  • WAIS, Rebecca J.
  • WHITEHEAD, Andrew P.
  • WONG, Charles C.
Priority Data
PCT/CN2018/10900330.09.2018CN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER
(FR) COMPOSÉS DE CINNOLINE POUR LE TRAITEMENT DE TROUBLES DÉPENDANT DU HPK1 TELS QUE LE CANCER
Abstract
(EN) Cinnoline compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
(FR) L'invention concerne des composés de cinnoline de formule (I), leurs variantes et leur utilisation en tant qu'inhibiteurs de HPK1 (kinase hématopoïétique 1). Les composés sont utiles dans le traitement de troubles dépendant de HPK1 et l'amélioration d'une réponse immunitaire. L'invention concerne également des procédés d'inhibition de HPK1, des procédés de traitement de troubles dépendant de HPK1, des procédés d'amélioration d'une réponse immunitaire, et des procédés de préparation des composés de cinnoline.
Related patent documents
Latest bibliographic data on file with the International Bureau